Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA-PDT for Facial Actinic Keratosis
NCT03642535Phase 4Unknown
- Sponsor
- Shanghai Skin Disease Hospital
- Start
- Aug 2018
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of aminolevulinic acid 10% gel in actinic keratosis (AK) (2 arms), sponsored by Shanghai Skin Disease Hospital. Primary endpoint: Number of new Actinic Keratoses at 36 months. Status: unknown.
02
Drugs
aminolevulinic acid 10% gel
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03642535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642535.